ADCT: Q2 2026 delivered stable sales, improved losses, and regulatory challenges for ZYNLONTA
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw stable ZYNLONTA sales and improved net loss, with $18.6M in revenue and $219.1M cash on hand. Regulatory uncertainty persists after FDA concerns on LOTIS-5, but growth is anticipated in 2027 as new data and trials progress.Original document: ADC Therapeutics SA [ADCT] SEC 6-K Current Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw stable ZYNLONTA sales and improved net loss, with $18.6M in revenue and $219.1M cash on hand. Regulatory uncertainty persists after FDA concerns on LOTIS-5, but growth is anticipated in 2027 as new data and trials progress.
Original document: ADC Therapeutics SA [ADCT] SEC 6-K Current Report — Aug. 13 2026